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1. INTRODUCTION {#jcla23341-sec-0005}
===============

Cancer is one of the most common diseases and has become a serious public health problem worldwide. In the United States, 1 735 350 new cancer cases and 609 640 cancer deaths are estimated to occur in 2018.[^1^](#jcla23341-bib-0001){ref-type="ref"} In China, it is estimated that there will be about 12 000 new cancer diagnoses and over 7500 cancer deaths on average each day in 2015.[^2^](#jcla23341-bib-0002){ref-type="ref"} One of the important reasons for high mortality and morbidity is the lack of effective screening and detection methods. Currently, traditional tumor markers such as carcinoembryonic antigen, carbohydrate antigen 199 and carbohydrate antigen 125 (CA125), are widely used in clinical practice, but their sensitivity (SEN) and specificity (SPE) are unsatisfied.[^3^](#jcla23341-bib-0003){ref-type="ref"}, [^4^](#jcla23341-bib-0004){ref-type="ref"}, [^5^](#jcla23341-bib-0005){ref-type="ref"} Therefore, identifying potential biomarkers for early detection and diagnosis of cancer is urgently needed.

Exosomes are small 40‐100 nm vesicles delivered by many cells of the organism, including cancer cells.[^6^](#jcla23341-bib-0006){ref-type="ref"} They can be found in all body fluids and play a key role in intercellular communication, which provide information on various different cellular functions and disease states where they can constitute valuable biomarkers.[^6^](#jcla23341-bib-0006){ref-type="ref"}, [^7^](#jcla23341-bib-0007){ref-type="ref"} Tumor‐derived exosomes transfer messages from tumor cells to tumor stroma, premetastatic niche, hematopoietic system, and non‐cancer stem cells by cancer‐initiating cells.[^8^](#jcla23341-bib-0008){ref-type="ref"} They contain abundant different types of proteins, nucleic acids, and lipids, which act important roles in tumorigenesis, growth, progression, metastasis, immune escape, and drug resistance as well as treatment of cancer.[^9^](#jcla23341-bib-0009){ref-type="ref"} Owing to their enriched contents and excellent stability, exosomes are suggested to be optimal noninvasive biomarkers for cancer diagnosis.[^10^](#jcla23341-bib-0010){ref-type="ref"} Increasing studies have shown that exosomes are considered to be a promising diagnostic biomarkers for various types of cancer.[^11^](#jcla23341-bib-0011){ref-type="ref"}, [^12^](#jcla23341-bib-0012){ref-type="ref"} However, due to small sample sizes and various exosomal marker types, there is still heterogeneity or inconsistency in the diagnostic accuracy of exosomes. Thus, we performed the meta‐analysis to precisely assess the overall diagnostic accuracy of circulating exosomes in human cancer.

2. MATERIALS AND METHODS {#jcla23341-sec-0006}
========================

2.1. Search strategy {#jcla23341-sec-0007}
--------------------

A comprehensive and systematic search was conducted in PubMed, Embase, and Cochrane Library up to June 27, 2019. Search terms were as follows: (cancer OR carcinoma OR tumor OR tumour OR neoplasm) AND (circulating OR serum OR plasma OR blood) AND (exosome OR exosomes OR exosomal) AND (diagnosis OR diagnostic OR sensitivity OR specificity OR "receiver operating characteristic curve" OR ROC). The literature search was performed independently by two authors (DMG and JPY). Any disagreements between the two authors were resolved by discussion with a third author (JTC).

2.2. Inclusion and exclusion criteria {#jcla23341-sec-0008}
-------------------------------------

The inclusion criteria for literature were as follows: (a) studies investigated diagnostic value of exosomal markers for any type of human cancers; (b) exosomes were isolated from serum or plasma; (c) studies included cancer cases and benign or healthy controls; and (d) studies provided sufficient data to construct a diagnostic 2 × 2 table. The exclusion criteria included the following: (a) studies that did not relate to exosomes or cancer; (b) studies that were duplicate articles, reviews, animal studies, editorials, case reports, comments, method articles, expert opinions, conference abstracts, and meta‐analyses; (c) studies with at least 20 cases and 20 controls; (dd) studies without complete data; (e) studies with no difference in expression of markers; and (f) studies that were not published in English.

2.3. Data extraction and quality assessment {#jcla23341-sec-0009}
-------------------------------------------

Information from eligible literatures was independently extracted by two investigators (DMG and JPY). The following data from included studies were collected: first author, publication year, country, exosomal biomarker type, cancer type, sample type, isolation methods, number of case and control, and diagnostic value, including SEN, SPE, true‐positive (TP), false‐positive (FP), false‐negative (FN), and true‐negative (TN). The quality of each study was assessed independently by two authors (DMG and JPY) using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS‐2),[^13^](#jcla23341-bib-0013){ref-type="ref"} which consists of four domains: patient selection, index text, reference standard, and flow and timing. Any discrepancies between the two authors were resolved by a third author (XXL).

2.4. Statistical analysis {#jcla23341-sec-0010}
-------------------------

The meta‐analysis was conducted by RevMan5.3, Meta‐DiSc 1.4, and STATA 15.1 software. The heterogeneity of the study was estimated by the Cochran\'s Q test and *I* ^2^ index.[^14^](#jcla23341-bib-0014){ref-type="ref"} *P* \< .05 for *Q* test or *I* ^2^ \> 50% indicated the existence of heterogeneity. A bivariate mixed‐effects model was used to calculate the pooled SEN, SPE, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR) with 95% confidence intervals (95% CI). Summary receiver operator characteristic (SROC) curve and forest plots of pooled SEN and SPE were applied to evaluate the diagnostic performance of circulating exosomes. Spearman\'s correlation coefficient and ROC plane were used to assess the heterogeneity generated by diagnostic threshold effect. Meta‐regression and subgroup analysis were performed to investigate the heterogeneity generated by non‐threshold effect. In addition, a bivariate box plot was used to evaluate the potential source of heterogeneity within the selected studies. The clinical practicality of circulating exosomes was examined by Fagan\'s nomogram. Moreover, sensitivity analysis and Deeks\' funnel plot asymmetry test were constructed to test the stability of pooled HR and publication bias, respectively.

3. RESULTS {#jcla23341-sec-0011}
==========

3.1. Search results {#jcla23341-sec-0012}
-------------------

The flow diagram of article selection is presented in Figure [1A](#jcla23341-fig-0001){ref-type="fig"}. A total of 3334 literatures were searched from PubMed, Embase, and Cochrane Library. After removing 865 duplicate publications, 2469 articles were included for further assessing. After screening of the title and abstract, 2342 articles were excluded and the remaining 127 literatures were further evaluated. After detailed evaluation of the full texts, 85 articles were excluded for the following reasons: (a) 34 studies not for diagnostic research; (b) 34 studies with insufficient data; (c) 7 studies based on combined diagnosis; (d) 1 study with no difference in expression; (e) 6 studies with sample size less than 20 in either case or control group; and (f) 3 studies with non‐English full‐text. Finally, a total of 70 studies from 42 publications[^15^](#jcla23341-bib-0015){ref-type="ref"}, [^16^](#jcla23341-bib-0016){ref-type="ref"}, [^17^](#jcla23341-bib-0017){ref-type="ref"}, [^18^](#jcla23341-bib-0018){ref-type="ref"}, [^19^](#jcla23341-bib-0019){ref-type="ref"}, [^20^](#jcla23341-bib-0020){ref-type="ref"}, [^21^](#jcla23341-bib-0021){ref-type="ref"}, [^22^](#jcla23341-bib-0022){ref-type="ref"}, [^23^](#jcla23341-bib-0023){ref-type="ref"}, [^24^](#jcla23341-bib-0024){ref-type="ref"}, [^25^](#jcla23341-bib-0025){ref-type="ref"}, [^26^](#jcla23341-bib-0026){ref-type="ref"}, [^27^](#jcla23341-bib-0027){ref-type="ref"}, [^28^](#jcla23341-bib-0028){ref-type="ref"}, [^29^](#jcla23341-bib-0029){ref-type="ref"}, [^30^](#jcla23341-bib-0030){ref-type="ref"}, [^31^](#jcla23341-bib-0031){ref-type="ref"}, [^32^](#jcla23341-bib-0032){ref-type="ref"}, [^33^](#jcla23341-bib-0033){ref-type="ref"}, [^34^](#jcla23341-bib-0034){ref-type="ref"}, [^35^](#jcla23341-bib-0035){ref-type="ref"}, [^36^](#jcla23341-bib-0036){ref-type="ref"}, [^37^](#jcla23341-bib-0037){ref-type="ref"}, [^38^](#jcla23341-bib-0038){ref-type="ref"}, [^39^](#jcla23341-bib-0039){ref-type="ref"}, [^40^](#jcla23341-bib-0040){ref-type="ref"}, [^41^](#jcla23341-bib-0041){ref-type="ref"}, [^42^](#jcla23341-bib-0042){ref-type="ref"}, [^43^](#jcla23341-bib-0043){ref-type="ref"}, [^44^](#jcla23341-bib-0044){ref-type="ref"}, [^45^](#jcla23341-bib-0045){ref-type="ref"}, [^46^](#jcla23341-bib-0046){ref-type="ref"}, [^47^](#jcla23341-bib-0047){ref-type="ref"}, [^48^](#jcla23341-bib-0048){ref-type="ref"}, [^49^](#jcla23341-bib-0049){ref-type="ref"}, [^50^](#jcla23341-bib-0050){ref-type="ref"}, [^51^](#jcla23341-bib-0051){ref-type="ref"}, [^52^](#jcla23341-bib-0052){ref-type="ref"}, [^53^](#jcla23341-bib-0053){ref-type="ref"}, [^54^](#jcla23341-bib-0054){ref-type="ref"}, [^55^](#jcla23341-bib-0055){ref-type="ref"}, [^56^](#jcla23341-bib-0056){ref-type="ref"} involving 3161 cases and 2763 controls were analyzed in the meta‐analysis.

![Flow diagram of studies\' selection and quality assessment of the included articles](JCLA-34-e23341-g001){#jcla23341-fig-0001}

3.2. Study characteristics and quality assessments {#jcla23341-sec-0013}
--------------------------------------------------

The main characteristics of included articles are provided in Table [1](#jcla23341-tbl-0001){ref-type="table"}. All cancer cases were confirmed pathologically. There were fifteen cancer types: lung cancer (LC, n = 7),[^15^](#jcla23341-bib-0015){ref-type="ref"}, [^16^](#jcla23341-bib-0016){ref-type="ref"}, [^17^](#jcla23341-bib-0017){ref-type="ref"}, [^18^](#jcla23341-bib-0018){ref-type="ref"}, [^19^](#jcla23341-bib-0019){ref-type="ref"}, [^20^](#jcla23341-bib-0020){ref-type="ref"}, [^21^](#jcla23341-bib-0021){ref-type="ref"} esophageal cancer (EC, n = 1),[^22^](#jcla23341-bib-0022){ref-type="ref"} gastric cancer (GC, n = 5),[^23^](#jcla23341-bib-0023){ref-type="ref"}, [^24^](#jcla23341-bib-0024){ref-type="ref"}, [^25^](#jcla23341-bib-0025){ref-type="ref"}, [^26^](#jcla23341-bib-0026){ref-type="ref"}, [^27^](#jcla23341-bib-0027){ref-type="ref"} colorectal cancer (CRC, n = 5),[^28^](#jcla23341-bib-0028){ref-type="ref"}, [^29^](#jcla23341-bib-0029){ref-type="ref"}, [^30^](#jcla23341-bib-0030){ref-type="ref"}, [^31^](#jcla23341-bib-0031){ref-type="ref"}, [^32^](#jcla23341-bib-0032){ref-type="ref"} hepatocellular carcinoma (HCC, n = 4),[^33^](#jcla23341-bib-0033){ref-type="ref"}, [^34^](#jcla23341-bib-0034){ref-type="ref"}, [^35^](#jcla23341-bib-0035){ref-type="ref"}, [^36^](#jcla23341-bib-0036){ref-type="ref"} pancreatic cancer (PC, n = 3),[^37^](#jcla23341-bib-0037){ref-type="ref"}, [^38^](#jcla23341-bib-0038){ref-type="ref"}, [^39^](#jcla23341-bib-0039){ref-type="ref"} ovarian cancer (OC, n = 3),[^40^](#jcla23341-bib-0040){ref-type="ref"}, [^41^](#jcla23341-bib-0041){ref-type="ref"}, [^42^](#jcla23341-bib-0042){ref-type="ref"} glioma (n = 3),[^43^](#jcla23341-bib-0043){ref-type="ref"}, [^44^](#jcla23341-bib-0044){ref-type="ref"}, [^45^](#jcla23341-bib-0045){ref-type="ref"} clear cell renal cell carcinoma (ccRCC, n = 2),[^50^](#jcla23341-bib-0050){ref-type="ref"}, [^51^](#jcla23341-bib-0051){ref-type="ref"} bladder cancer (BC, n = 3),[^46^](#jcla23341-bib-0046){ref-type="ref"}, [^48^](#jcla23341-bib-0048){ref-type="ref"}, [^49^](#jcla23341-bib-0049){ref-type="ref"} prostate cancer (PCa, n = 2),[^47^](#jcla23341-bib-0047){ref-type="ref"}, [^52^](#jcla23341-bib-0052){ref-type="ref"} osteosarcoma (n = 1),[^53^](#jcla23341-bib-0053){ref-type="ref"} multiple myeloma (MM, n = 1),[^54^](#jcla23341-bib-0054){ref-type="ref"} melanoma (n = 1),[^55^](#jcla23341-bib-0055){ref-type="ref"} and laryngeal squamous cell carcinoma (LSCC, n = 1).[^56^](#jcla23341-bib-0056){ref-type="ref"} Publication years of all included researches range from 2013 to 2019. Fifty‐nine studies were based on serum and eleven studies based on plasma. The sample sizes of the studies ranged from 40 to 468, and 35 studies included at least 110 participants. Of the seventy studies, thirty studies focused on microRNAs (miRNAs), twenty‐two studies focused on long non‐coding RNAs (lncRNAs), twelve studies focused on proteins, and six studies focused on other markers (circular RNA, messenger RNA, and small non‐coding RNA). The results of study quality assessment were evaluated using QUADAS‐2 (Figure [1B](#jcla23341-fig-0001){ref-type="fig"} and Figure [S1](#jcla23341-sup-0001){ref-type="supplementary-material"}). Most studies had low or unclear risks of bias on patient selection, index text, reference standard, and flow and timing, indicating that the quality of included studies was medium.

###### 

Basic characteristics of the 42 eligible studies

  Author                   Year       Country   Exosomal markers      Cancer type    Specimen   Isolation method      Case   Control   TP    FP   FN   TN
  ------------------------ ---------- --------- --------------------- -------------- ---------- --------------------- ------ --------- ----- ---- ---- -----
  Wang et al               2018       China     Protein               LC             Serum      Ultracentrifugation   183    90        119   22   64   68
  Zhang et al              2019       China     miRNA                 LC             Serum      Isolation kit         100    90        70    16   30   74
  miRNA                    LC         Serum     Isolation kit         72             47         48                    11     24        36              
  Sandfeld‐Paulsen et al   2016       Denmark   Protein               LC             Plasma     Ultracentrifugation   57     126       34    31   23   95
  Teng et al               2019       China     LncRNA                LC             Plasma     Ultracentrifugation   75     79        57    21   18   58
  Zhang et al              2017       China     LncRNA                LC             Serum      Isolation kit         77     30        46    6    31   24
  Li et al                 2019       China     LncRNA                LC             Serum      Isolation kit         64     40        55    12   9    28
  Niu et al                2019       China     Protein               LC             Serum      Ultracentrifugation   122    46        67    7    55   39
  Protein                  LC         Serum     Ultracentrifugation   109            46         84                    9      25        37              
  Zhao et al               2019       China     Protein               ESCC           Serum      Isolation kit         100    100       75    15   25   85
  Yang et al               2018       China     miRNA                 GC             Serum      Isolation kit         80     80        65    34   15   46
  Zhao et al               2018       China     LncRNA                GC             Serum      Ultracentrifugation   126    120       88    18   38   102
  Pan et al                2017       China     LncRNA                GC             Serum      Ultracentrifugation   40     37        32    9    8    28
  Lin et al                2018       China     LncRNA                GC             Plasma     Ultracentrifugation   51     60        45    10   6    50
  LncRNA                   GC         Plasma    Ultracentrifugation   51             60         46                    26     5         34              
  Rahbari et al            2019       Germany   Protein               GC             Serum      Isolation kit         49     56        42    14   7    42
  Barbagallo et al         2018       Italy     LncRNA                CRC            Serum      Isolation kit         20     20        20    11   0    9
  circRNA                  CRC        Serum     Isolation kit         20             20         14                    4      6         16              
  Liu et al                2016       China     LncRNA                CRC            Serum      Isolation kit         148    320       104   18   44   302
  Liu et al                2018       China     miRNA                 CRC            Plasma     Isolation kit         80     40        64    9    16   31
  miRNA                    CRC        Plasma    Isolation kit         80             40         56                    8      24        32              
  Liu et al                2018       China     miRNA                 CRC            Plasma     Isolation kit         53     30        37    7    16   23
  Sun et al                2019       China     Protein               CRC            Plasma     Ultracentrifugation   92     32        62    5    30   27
  Abd El Gwad et al        2018       Egypt     LncRNA                HCC            Serum      Isolation kit         60     60        58    3    2    57
  miRNA                    HCC        Serum     Isolation kit         60             60         57                    12     3         48              
  mRNA                     HCC        Serum                           60             60         45                    16     15        44              
  Xu et al                 2018       China     mRNA                  HCC            Serum      Isolation kit         88     68        75    16   13   52
  mRNA                     HCC        Serum     Isolation kit         88             67         76                    16     12        36              
  Wang et al               2018       China     miRNA                 HCC            Serum      Ultracentrifugation   50     50        50    4    0    46
  Xu et al                 2018       China     LncRNA                HCC            Serum      Isolation kit         60     96        43    16   17   80
  LncRNA                   HCC        Serum     Isolation kit         55             60         40                    12     15        48              
  LncRNA                   HCC        Serum     Isolation kit         60             96         46                    21     14        75              
  LncRNA                   HCC        Serum     Isolation kit         55             60         44                    15     11        45              
  Que et al                2013       China     miRNA                 PC             Serum      Ultracentrifugation   22     27        16    2    6    25
  miRNA                    PC         Serum     Ultracentrifugation   22             27         21                    5      1         22              
  Goto et al               2018       Japan     miRNA                 PC             Serum      Isolation kit         32     22        23    3    9    19
  miRNA                    PC         Serum     Isolation kit         32             22         26                    4      6         18              
  miRNA                    PC         Serum     Isolation kit         32             22         21                    3      11        19              
  Melo et al               2015       USA       Protein               PC             Serum      Ultracentrifugation   190    126       190   0    0    126
  Protein                  PC         Serum     Ultracentrifugation   26             56         56                    0      0         26              
  Meng et al               2016       Germany   miRNA                 OC             Serum      Isolation kit         112    20        94    2    18   18
  miRNA                    OC         Serum     Isolation kit         112            20         59                    0      53        20              
  miRNA                    OC         Serum     Isolation kit         112            20         35                    0      77        20              
  Kim et al                2019       Korea     miRNA                 OC             Serum      Isolation kit         48     20        44    5    4    15
  miRNA                    OC         Serum     Isolation kit         48             20         35                    2      13        18              
  Su et al                 2019       China     miRNA                 OC             Serum      Isolation kit         50     65        31    8    19   57
  miRNA                    OC         Serum     Isolation kit         50             65         17                    4      33        61              
  Santangelo et al         2018       Italy     miRNA                 Glioma         Serum      Isolation kit         60     30        49    7    11   23
  miRNA                    Glioma     Serum     Isolation kit         60             30         36                    1      24        29              
  miRNA                    Glioma     Serum     Isolation kit         60             30         50                    11     10        19              
  Shao et al               2019       China     miRNA                 Glioma         Serum      Isolation kit         24     24        19    2    5    22
  Manterola et al          2014       Spain     sncRNA                Glioma         Serum      Isolation kit         50     30        33    10   17   20
  sncRNA                   Glioma     Serum     Isolation kit         25             25         18                    7      7         18              
  miRNA                    Glioma     Serum     Isolation kit         25             25         16                    9      9         16              
  miRNA                    Glioma     Serum     Isolation kit         25             25         15                    10     10        15              
  Wang et al               2018       China     LncRNA                BC             Serum      Isolation kit         52     104       39    23   13   81
  Li et al                 2018       China     Protein               PCa            Serum      Ultracentrifugation   50     21        44    4    6    17
  Zheng et al              2018       China     LncRNA                BC             Plasma     Isolation kit         50     60        33    9    17   51
  Xue et al                2017       China     LncRNA                BC             Serum      Isolation kit         30     30        24    5    6    25
  Zhang et al              2018       China     miRNA                 ccRCC          Serum      Isolation kit         82     80        57    30   25   50
  miRNA                    ccRCC      Serum     Isolation kit         82             80         66                    19     16        61              
  Wang et al               2019       China     miRNA                 ccRCC          Serum      Isolation kit         40     30        33    6    7    24
  Wang et al               2018       China     LncRNA                PCa            Plasma     Isolation kit         34     30        21    5    13   25
  LncRNA                   PCa        Plasma    Isolation kit         34             30         30                    7      4         23              
  Yuan et al               2019       China     LncRNA                Osteosarcoma   Serum      Isolation kit         46     45        40    15   6    30
  Sedlarikova et al        2018       Czech     LncRNA                MM             Serum      Isolation kit         50     30        40    7    10   23
  Alegre et al             2016       Spain     Protein               Melanoma       Serum      Isolation kit         53     25        42    5    11   20
  Protein                  Melanoma   Serum     Isolation kit         53             25         42                    5      11        20              
  Wang et al               2014       China     miRNA                 LSCC           Serum      Isolation kit         52     49        36    10   10   40
  LncRNA                   LSCC       Serum     Isolation kit         52             49         48                    9      16        28              

Abbreviations: BC, bladder cancer; CRC, colorectal cancer; ESCC, esophageal squamous cell carcinoma; FN, false negatives; FP, false positives; GC, gastric cancer; HCC, hepatocellular carcinoma; LC, lung cancer; LSCC, laryngeal squamous cell carcinoma; MM, multiple myeloma; OC, ovarian cancer; PC, pancreatic cancer; PCa, prostate cancer; TN, true negatives; TP, true positives.
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3.3. Diagnostic accuracy {#jcla23341-sec-0014}
------------------------

Threshold and non‐threshold effects are sources of heterogeneity on diagnostic tests. Heterogeneity caused by non‐threshold effects was evaluated using Q tests and I‐squared. The pooled SEN (*I* ^2^ = 86.81%, *P* \< .01) and specificity (*I* ^2^ = 77.27%, *P* \< .01) revealed significant heterogeneity (Figure [2](#jcla23341-fig-0002){ref-type="fig"}). We conducted Spearman\'s correlation coefficient and ROC plane to identify heterogeneity generated by threshold effects. Spearman\'s correlation coefficient was 0.200 (*P* = .097), and ROC plane did not show the typical shoulder arm (Figure [3A](#jcla23341-fig-0003){ref-type="fig"}), suggesting that no threshold effects were found.

![Forest plot of sensitivity and specificity of circulating exosomes for the diagnosis of cancer. CI, confidence interval; Q, Cochran\'s Q value; DF, degrees of freedom; I^2^, inconsistency index](JCLA-34-e23341-g002){#jcla23341-fig-0002}

![Diagnostic accuracy of included studies in our meta‐analysis. (A) ROC plane. (B) SROC curve. (C) Fagan\'s nomogram. (D) Meta‐regression plot. (E) Bivariate boxplot. (F) Deeks\' funnel plot](JCLA-34-e23341-g003){#jcla23341-fig-0003}

The forest plots showed that pooled SEN and SPE were 0.79 (95% CI: 0.75‐0.82) and 0.81 (95% CI: 0.78‐0.84), respectively. SROC curve exhibited that the overall AUC was 0.87 (95% CI: 0.84‐0.89) (Figure [3B](#jcla23341-fig-0003){ref-type="fig"}). In addition, the pooled PLR, NLR, and DOR were 4.1 (95% CI: 3.5‐4.8), 0.26 (95% CI: 0.22‐0.31), and 16 (95% CI: 12‐21), respectively. Fagan\'s diagram was applied to assess the predictive value on clinical utility. With a pretest probability of 20%, Fagan\'s diagram exhibited that the positive posttest probability of accurately diagnosing cancer would increase to 51%, while the negative probability would drop to 6% (Figure [3C](#jcla23341-fig-0003){ref-type="fig"}).

3.4. Meta‐regression and subgroup analysis {#jcla23341-sec-0015}
------------------------------------------

To investigate potential sources of heterogeneity, meta‐regression and subgroup analysis were performed based on type of cancer (LC or not, CRC or not, GC or not, HCC or not, OC or not), sample type (serum or plasma), sample size (≥110 or \<110), and exosomal markers (miRNA or not, lncRNA or not, protein or not) (Figure [3D](#jcla23341-fig-0003){ref-type="fig"}). The exact results of meta‐regression analysis are presented in Table [2](#jcla23341-tbl-0002){ref-type="table"}. We found that research country, LC, CRC, HCC, OC, sample type, isolation method, sample size, exosomal miRNAs, exosomal lncRNAs, and exosomal proteins were likely the sources of heterogeneity in sensitivity. We also found that research country, LC, GC, CRC, HCC, sample type, isolation method, sample size, exosomal miRNAs, exosomal lncRNAs, and exosomal proteins might act as sources of heterogeneity in specificity. As shown in bivariate boxplot (Figure [3E](#jcla23341-fig-0003){ref-type="fig"}), there were 19 studies not located in the boxplot. After removing these studies, the heterogeneity among studies decreased obviously (SEN: *I* ^2^ = 64.28%, *P* \< .01 and SPE: *I* ^2^ = 36.52%, *P* = .01). The results of subgroup analysis are summarized in Table [3](#jcla23341-tbl-0003){ref-type="table"}. Studies about HCC or OC exhibited larger AUC (0.90, 95% CI: 0.87‐0.92 and 0.90, 95% CI: 0.87‐0.93, respectively) compared with other cancer types. Studies involving serum presented higher SEN (0.79, 95% CI: 0.75‐0.83), SPE (0.82, 95% CI: 0.78‐0.83), PLR (4.3, 95% CI: 3.6‐5.2), DOR (17, 95% CI: 12‐24), and AUC (0.88, 95% CI: 0.84‐0.90) than those involving plasma. In addition, exosomal proteins demonstrated superior SEN (0.86, 95% CI: 0.66‐0.95), SPE (0.87, 95% CI: 0.78‐0.93), and AUC (0.93, 95% CI: 0.90‐0.95) compared to exosomal miRNAs or lncRNAs.

###### 

The results of meta‐regression analysis

  Parameter           Category   N                  SEN (95% CI)       *P*      SPE (95% CI)       *P*
  ------------------- ---------- ------------------ ------------------ -------- ------------------ --------
  China               Yes        43                 0.77 (0.73‐0.82)   \<.001   0.80 (0.76‐0.83)   \<.001
  No                  27         0.80 (0.75‐0.86)   0.83 (0.79‐0.87)                               
  LC                  Yes        9                  0.69 (0.58‐0.81)   \<.001   0.78 (0.70‐0.86)   \<.001
  No                  61         0.80 (0.76‐0.83)   0.81 (0.78‐0.84)                               
  GC                  Yes        6                  0.84 (0.74‐0.94)   .10      0.74 (0.63‐0.85)   \<.001
  No                  64         0.78 (0.74‐0.82)   0.82 (0.79‐0.85)                               
  CRC                 Yes        7                  0.76 (0.64‐0.89)   .01      0.81 (0.72‐0.90)   \<.001
  No                  63         0.79 (0.75‐0.83)   0.81 (0.78‐0.84)                               
  HCC                 Yes        10                 0.87 (0.80‐0.93)   .04      0.80 (0.73‐0.87)   \<.001
  No                  60         0.77 (0.73‐0.81)   0.81 (0.78‐0.84)                               
  OC                  Yes        7                  0.63 (0.49‐0.78)   \<.001   0.92 (0.87‐0.97)   .17
  No                  63         0.80 (0.76‐0.83)   0.80 (0.77‐0.83)                               
  Serum               Yes        59                 0.79 (0.75‐0.83)   .01      0.82 (0.78‐0.85)   \<.001
  No                  11         0.76 (0.66‐0.86)   0.78 (0.71‐0.86)                               
  Isolation Kit       Yes        54                 0.77 (0.72‐0.81)   \<.001   0.80 (0.76‐0.83)   \<.001
  No                  16         0.85 (0.79‐0.91)   0.85 (0.80‐0.89)                               
  Sample size ≥ 110   Yes        35                 0.76 (0.71‐0.81)   \<.001   0.82 (0.79‐0.86)   \<.001
  No                  35         0.81 (0.77‐0.86)   0.79 (0.75‐0.84)                               
  miRNA               Yes        30                 0.75 (0.69‐0.81)   \<.001   0.83 (0.78‐0.87)   \<.001
  No                  40         0.81 (0.77‐0.85)   0.80 (0.76‐0.84)                               
  LncRNA              Yes        22                 0.81 (0.75‐0.87)   \<.001   0.79 (0.74‐0.84)   \<.001
  No                  48         0.77 (0.73‐0.82)   0.82 (0.79‐0.85)                               
  Protein             Yes        12                 0.82 (0.75‐0.90)   \<.01    0.85 (0.80‐0.91)   \<.001
  No                  58         0.78 (0.74‐0.82)   0.80 (0.77‐0.83)                               

Abbreviations: CRC, colorectal cancer; GC, gastric cancer; HCC, hepatocellular carcinoma; LC, lung cancer; OC, ovarian cancer; SEN, sensitivity; SPE, specificity.

John Wiley & Sons, Ltd

###### 

The results of subgroup analysis for diagnostic value

  Subgroup                   N    SEN (95% CI)       SPE (95% CI)       PLR (95% CI)     NLR (95% CI)       DOR (95% CI)   AUC (95% CI)
  -------------------------- ---- ------------------ ------------------ ---------------- ------------------ -------------- ------------------
  Overall                    70   0.79 (0.75‐0.82)   0.81 (0.78‐0.84)   4.1 (3.5‐4.8)    0.26 (0.22‐0.31)   16 (12‐21)     0.87 (0.84‐0.89)
  Type of cancer                                                                                                           
  Lung cancer                9    0.69 (0.62‐0.75)   0.77 (0.73‐0.81)   3.0 (2.6‐3.5)    0.40 (0.33‐0.49)   7 (6‐10)       0.80 (0.76‐0.83)
  Colorectal cancer          7    0.75 (0.68‐0.80)   0.81 (0.68‐0.90)   4.0 (2.3‐6.7)    0.31 (0.26‐0.38)   13 (7‐23)      0.81 (0.77‐0.84)
  Gastric cancer             6    0.82 (0.75‐0.87)   0.73 (0.63‐0.81)   3.1 (2.2‐4.2)    0.24 (0.18‐0.33)   13 (8‐20)      0.85 (0.82‐0.88)
  Hepatocellular carcinoma   10   0.87 (0.78‐0.93)   0.80 (0.73‐0.86)   4.5 (3.0‐6.7)    0.16 (0.09‐0.30)   28 (11‐73)     0.90 (0.87‐0.92)
  Ovarian cancer             7    0.64 (0.45‐0.80)   0.91 (0.84‐0.95)   7.1 (4.4‐11.3)   0.39 (0.24‐0.63)   18 (10‐33)     0.90 (0.87‐0.93)
  Other cancers              31   0.81 (0.75‐0.85)   0.81 (0.76‐0.86)   4.3 (3.2‐5.9)    0.24 (0.17‐0.32)   18 (10‐33)     0.88 (0.85‐0.91)
  Sample type                                                                                                              
  Serum                      59   0.79 (0.75‐0.83)   0.82 (0.78‐0.85)   4.3 (3.6‐5.2)    0.25 (0.21‐0.31)   17 (12‐24)     0.88 (0.84‐0.90)
  Plasma                     11   0.75 (0.68‐0.81)   0.77 (0.72‐0.82)   3.3 (2.7‐4.0)    0.32 (0.26‐0.41)   10 (7‐14)      0.83 (0.79‐0.86)
  Isolation method                                                                                                         
  Isolation kit              54   0.76 (0.73‐0.80)   0.80 (0.76‐0.83)   3.8 (3.3‐4.4)    0.30 (0.26‐0.34)   13 (10‐16)     0.85 (0.82‐0.88)
  Ultracentrifugation        16   0.88 (0.74‐0.95)   0.86 (0.78‐0.92)   6.3 (3.6‐11.2)   0.14 (0.06‐0.33)   46 (11‐187)    0.93 (0.90‐0.95)
  Sample size                                                                                                              
  ≥110                       35   0.76 (0.70‐0.81)   0.83 (0.78‐0.86)   4.4 (3.4‐5.6)    0.29 (0.23‐0.37)   15 (10‐23)     0.87 (0.83‐0.89)
  ＜110                      35   0.81 (0.76‐0.85)   0.79 (0.75‐0.82)   3.8 (3.2‐4.6)    0.24 (0.19‐0.30)   16 (11‐23)     0.86 (0.83‐0.89)
  Exosomal biomarkers                                                                                                      
  miRNA                      30   0.75 (0.68‐0.80)   0.83 (0.78‐0.87)   4.3 (3.4‐5.5)    0.31 (0.24‐0.38)   14 (10‐20)     0.86 (0.83‐0.89)
  LncRNA                     22   0.81 (0.76‐0.85)   0.79 (0.73‐0.83)   3.8 (3.1‐4.7)    0.25 (0.20‐0.31)   15 (11‐21)     0.87 (0.83‐0.89)
  Protein                    12   0.86 (0.66‐0.95)   0.87 (0.78‐0.93)   6.9 (3.2‐14.6)   0.16 (0.05‐0.46)   44 (7‐263)     0.93 (0.90‐0.95)
  Other markers              6    0.78 (0.70‐0.84)   0.70 (0.62‐0.78)   2.6 (2.0‐3.4)    0.32 (0.24‐0.42)   8 (5‐13)       0.80 (0.77‐0.84)

Abbreviations: AUC, area under the curve; DOR, diagnostic odds ratio; NLR, negative likelihood ratio; PLR, positive likelihood ratio; SEN, sensitivity; SPE, specificity.

John Wiley & Sons, Ltd

3.5. Sensitivity analysis and publication bias {#jcla23341-sec-0016}
----------------------------------------------

To further explore the potential heterogeneity from any single study, sensitivity analysis was performed and showed that our results were not significantly affected by removing any study (Figure [4](#jcla23341-fig-0004){ref-type="fig"}). Deeks\' funnel plot asymmetry test was applied to examine publication bias for studies. As shown in Figure [2F](#jcla23341-fig-0002){ref-type="fig"}, A *P* value of .093 (*P* \> .05) suggested no obvious publication bias among these studies.

![Sensitivity analysis of the overall pooled study](JCLA-34-e23341-g004){#jcla23341-fig-0004}

4. DISCUSSION {#jcla23341-sec-0017}
=============

In the last few years, the potential diagnostic significance of circulating exosomes has been intensively investigated in various diseases, especially in the field of cancer research. Several previous meta‐analyses have published the diagnostic value of exosomes in cancer. However, Yang et al[^11^](#jcla23341-bib-0011){ref-type="ref"} focused only on exosomal miRNAs in their meta‐analysis. Wong et al[^12^](#jcla23341-bib-0012){ref-type="ref"} did not conduct the overall diagnostic value in cancer, and the number of articles included in their meta‐analysis was evidently less than ours. Our study, involving 5924 participants (3161 cases and 2763 controls), and 15 types of cancer, is the first study to comprehensively assess overall diagnostic value of circulating exosomes in human cancer through a meta‐analysis. The quality assessment of the included studies was conducted, which exhibited moderate quality. The overall pooled SEN, SPE, and AUC were 0.79 (95% CI: 0.75‐0.82), 0.81 (95% CI: 0.78‐0.84), and 0.87 (95% CI: 0.83‐0.89), respectively. These results indicated that circulating exosomes had relatively high diagnostic accuracy for cancer.

There was significant heterogeneity in the meta‐analysis. Spearman\'s correlation coefficient was 0.200, and ROC plane showed the absence of typical shoulder arm, meaning heterogeneity was not from threshold effects. Meta‐regression analysis was performed to identify heterogeneity caused by non‐threshold effects. Our analysis showed that the heterogeneity resulted from research country, cancer type, specimen, isolation method, sample size, and type of exosomal marker. Moreover, there were 19 studies that did not locate in bivariate boxplot, suggesting that the results of these studies might be the main sources of heterogeneity.

According to subgroup analysis, HCC and OC demonstrated the largest AUC, implying that detection of circulating exosomes could be a promising approach for diagnosis of HCC and OC. Alpha‐fetoprotein (AFP) is the most widely used tumor marker in diagnosis of liver cancer. The meta‐analysis of Dai et al[^57^](#jcla23341-bib-0057){ref-type="ref"} reported that the AUC of AFP for diagnosis HCC was 0.84. Our results showed that the AUC of circulating exosomes was 0.90, suggesting that the diagnostic value of exosomes was superior to AFP. In addition, Liao et al[^58^](#jcla23341-bib-0058){ref-type="ref"} concluded that the AUC of CA125 was 0.84 for diagnosis of OC after analyzing 19 literatures. In our meta‐analysis, the AUC of blood‐based exosomes was 0.90, which exhibited higher value than CA125 in distinguishing OC from non‐OC. Additionally, among the included studies of HCC or OC, only one study by Wang et al exhibited high risk of bias on index text. Therefore, the results of these studies showing high efficacy for HCC and OC diagnosis are reliable.

The pooled SEN, SPE, PLR, DOR, and AUC of serum‐based exosomes were significantly higher than plasma‐based exosomes, meaning that serum seemed to be the better specimen for detection. Moreover, the proportion of low‐risk bias in study using serum as a sample was higher than those using plasma, which suggested that studies based on serum specimen had superior quality and reliability. Currently, there is no consensus on sample selection for isolating blood exosomes. When preparing serum, additional extracellular vesicles are released by activated platelets during clot formation,[^59^](#jcla23341-bib-0059){ref-type="ref"} which cannot originally represent the pathophysiological status of the circulating blood in patients and may influent exosome isolation. On the contrary, experimental results of exosomes may be affected by anticoagulants when using plasma as sample. For example, heparin and ethylenediaminetetraacetic acid interfere with polymerase chain reaction.[^60^](#jcla23341-bib-0060){ref-type="ref"} Clearly, it is urgent to establish and validate guidelines for preparation of samples for exosome research.

The included studies used two different methods to isolate blood exosomes. The quality of studies with ultracentrifugation method was inferior to those with isolation kit because of the lower percentage of low‐risk bias. Studies with ultracentrifugation method displayed higher diagnostic accuracy. Due to fewer included studies using this method in the meta‐analysis, more large‐sample studies are needed to confirm this finding. Purifying exosomes is a great challenge because their biophysical properties overlap with other secreted cell products. There are different methods of isolating exosomes, including ultracentrifugation, precipitation, immunoaffinity capturing, filtration techniques, and microfluidics,[^61^](#jcla23341-bib-0061){ref-type="ref"} which results in qualitative and quantitative variability in terms of extracting exosomes. Hence, exploring an effective and standard technique of exosome isolation is urgently required. Suitable sample type and effective isolation method for exosomes detection may further improve the value of cancer diagnosis.

Among the various types of exosomal markers, superior SEN, SPE, and AUC were observed in exosomal protein, implying that exosomal proteins were probably the optimal biomarkers. In this subgroup analysis, the studies with other exosomal markers exhibited highest quality according to the QUADAS‐2. Among other three types of exosomal biomarkers, the overall risks of bias were similar in each group. Owing to the variety of markers and cancer types, more large‐scale studies are required to explore a specific type of exosomal biomarker with high diagnostic accuracy for a certain type of cancer.

We used Deeks\' funnel plot to identify publication bias of enrolled studies, which did not show a very good symmetrical shape. Compared with other included studies, two studies deviated obviously from symmetry, suggesting a possible bias. These two studies were from the same article reported by Melo et al[^39^](#jcla23341-bib-0039){ref-type="ref"} After careful evaluation of this article, we believe that the possible bias was caused by statistical significance, because their studies revealed an AUC of 1.0 with a sensitivity and specificity of 100%. However, the *P*‐value of funnel plot asymmetry test was .093, confirming that significant publication bias did not exist in general.

There were still some limitations that could not be neglected in this meta‐analysis. First, most studies were from China, and the results might therefore not be universally applicable. Second, the inclusion of articles published only in English might result in publication bias. Third, there was significant heterogeneity among the included studies. Although we conducted subgroup analysis and meta‐regression to explore the sources of heterogeneity, the results did not fully explain the potential heterogeneity. Thus, more well‐designed and multicenter studies with larger sample size are needed to provide more valuable evidence.

In summary, the present meta‐analysis indicated that circulating exosomes could be used as effective and minimally invasive biomarkers for distinguishing cancer patients from non‐cancer individuals. Circulating exosomes showed higher diagnostic accuracy in patients with HCC or OC, serum‐based samples, and exosomal proteins.
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